Psoriasis decreases the anti-oxidation and anti-inflammation properties of high-density lipoprotein

Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids

Volumn 1841, Issue 12, 2014, Pages 1709-1715

  He, Lei ^a   Qin, Shucun ^b   Dang, Lin ^a   Song, Guohua ^b   Yao, Shutong ^b   Yang, Nana ^b   Li, Yuzhen ^a  

^a THE SECOND AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

^b TAISHAN MEDICAL UNIVERSITY   (China)

Author keywords

Anti inflammation; Anti oxidative property; High density lipoprotein; Psoriasis

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN 3; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; MALONALDEHYDE; OXIDIZED LOW DENSITY LIPOPROTEIN; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TUMOR NECROSIS FACTOR ALPHA; BIOLOGICAL MARKER;

ADULT; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; BIOLOGICAL ACTIVITY; CELL ADHESION; CELL MIGRATION; CELL MIGRATION ASSAY; CELL STIMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLAMMATION; LIPID BLOOD LEVEL; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; MACROPHAGE; MALE; MONOCYTE; MTT ASSAY; OXIDATION; OXIDATIVE STRESS; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; ULTRACENTRIFUGATION; BLOOD; METABOLISM; OXIDATION REDUCTION REACTION; PATHOLOGY; UMBILICAL VEIN ENDOTHELIAL CELL;

ADULT; BIOLOGICAL MARKERS; FEMALE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INFLAMMATION; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; MACROPHAGES; MALE; OXIDATION-REDUCTION; PSORIASIS;

EID: 84908546316     PISSN: 13881981     EISSN: 18792618     Source Type: Journal    
DOI: 10.1016/j.bbalip.2014.09.008     Document Type: Article

References (35)

1. K.R. Feingold, and C. Grunfeld Psoriasis: it's more than just the skin J. Lipid Res. 53 8 2012 1427 1429
2. I.M. Miller, C. Ellervik, and S. Yazdanyar Meta-analysis of psoriasis, cardiovascular disease, and associated risk factors J. Am. Acad. Dermatol. 69 6 2013 1014 1024
3. N.N. Mehta, R.S. Azfar, and D.B. Shin Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database Eur. Heart J. 31 8 2010 1000 1006
4. J.M. Gelfand, A.L. Neimann, and D.B. Shin Risk of myocardial infarction in patients with psoriasis JAMA 296 14 2006 1735 1741
5. A.L. Neimann, D.B. Shin, and X. Wang Prevalence of cardiovascular risk factors in patients with psoriasis J. Am. Acad. Dermatol. 55 5 2006 829 835
6. S. Gerdes, and U. Mrowietz Impact of comorbidities on the management of psoriasis Curr. Probl. Dermatol. 38 2009 21 36
7. A.M. Tobin, D.J. Veale, and O. Fitzgerald Cardiovascular disease and risk factors in patients with psoriasis and psoriatic arthritis J. Rheumatol. 37 7 2010 1386 1394
8. E. Esteve, W. Ricart, and J.M. Fernández-Real Dyslipidemia and inflammation: an evolutionary conserved mechanism Clin. Nutr. 24 1 2005 16 31
9. C. Besler, K. Heinrich, and L. Rohrer Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease J. Clin. Invest. 121 7 2011 2693 2708
10. W. Annema, N. Nijstad, and M. Tolle Myeloperoxidase and plasma amyloid A contribute to impaired in vivo reverse cholesterol transport during the acute phase response but not group IIA secretory phospholipase A (2) J. Lipid Res. 51 4 2010 743 754
11. M. Holzer, P. Wolf, and S. Curcic Psoriasis alters HDL composition and cholesterol efflux capacity J. Lipid Res. 53 8 2012 1618 1624
12. M. Holzer, P. Wolf, and M. Inzinger Anti-psoriatic therapy recovers high-density lipoprotein composition and function J. Invest. Dermatol. 134 3 2014 635 642
13. N.S. Tekin, I.O. Tekin, and F. Barut Accumulation of oxidized low-density lipoprotein in psoriatic skin and changes of plasma lipid levels in psoriatic patients Mediat. Inflamm. 2007 10.1155/2007/78454
14. R. Christine, M.D. Bruner, and R. Steven A systematic review of adverse effects associated with topical treatments for psoriasis Dermatol. Online J. 9 1 2003 Feb 2
15. T. Itahara, T. Suehiro, and Y. Ikeda Plasma paraoxonase and arylesterase activities in hemodialysis patients J. Atheroscler. Thromb. 7 3 2000 152 158
16. J.R. Nofer, M. van der Giet, and M. Tölle HDL induces NO-dependent vasorelaxation via the lysophospholipid receptorS1P3 113 4 2004 569 581
17. G. Song, M. Li, and H. Sang Hydrogen-rich water decreases serum LDL-cholesterol levels and improves HDL function in patients with potential metabolic syndrome J. Lipid Res. 54 7 2013 1884 1893
18. Y. Rikitake, K. Hirata, and S. Kawashima Inhibitory effect of inducible type nitric oxide synthase on oxidative modification of low density lipoprotein by vascular smooth muscle cells Atherosclerosis 136 1 1998 51 57
19. J.A. McCrohon, W. Jessup, and D.J. Handelsman Androgen exposure increases human monocyte adhesion to vascular endothelium and endothelial cell expression of vascular cell adhesion molecule-1 Circulation 99 17 1999 2317 2322
20. N. Yang, S. Yao, and M. Wang Apolipoprotein A-I mimetic peptide reverse D-4 F improves the biologicalfunctions of mouse bone marrow-derived late EPCs via PI3K/AKT/eNOS pathway Mol. Cell. Biochem. 377 1-2 2013 229 236
21. B.M. Akkara Veetil, E.L. Matteson, and H. Maradit-Kremers Trends in lipid profiles in patients with psoriasis: a population-based analysis BMC Dermatol. 2012 10.1186/1471-5945-12-20 (Journal Title advance online publication)
22. A. Pietrzak, A. Michalak-Stoma, and G. Chodorowska Lipid disturbances in psoriasis: an update Mediat. Inflamm. 2010 10.1155/2010/535612
23. M. Navab, G.M. Anantharamaiah, and S.T. Reddy HDL as a biomarker, potential therapeutic target, and therapy Diabetes 58 12 2009 2711 2717
24. T. Elango, H. Dayalan, and P. Gnanaraj Impact of methotrexate on oxidative stress and apoptosis markers in psoriatic patients Clin. Exp. Med. 2013 10.1007/s10238-013-0252-7 (Journal Title advance online publication)
25. V. Relhan, S.K. Gupta, and S. Dayal Blood thiols and malondialdehyde levels in psoriasis J. Dermatol. 29 7 2002 399 403
26. G1. Ferretti, T. Bacchetti, and A. Campanati Correlation between lipoprotein (a) and lipid peroxidation in psoriasis: role of the enzyme paraoxonase-1 Br. J. Dermatol. 166 1 2012 204 207
27. E.A. Dowlatshahi, E.A. van der Voort, and L.R. Arends Markers of systemic inflammation in psoriasis: a systematic review and meta-analysis Br. J. Dermatol. 169 2 2013 266 282
28. S. Coimbra, H. Oliveira, and F. Reis Circulating adipokine levels in Portuguese patients with psoriasis vulgaris according to body mass index, severity and therapy J. Eur. Acad. Dermatol. Venereol. 24 12 2010 1386 1394
29. H. Takahashi, H. Tsuji, and Y. Hashimoto Serum cytokines and growth factor levels in Japanese patients with psoriasis Clin. Exp. Dermatol. 35 6 2010 645 649
30. T. Gordon, W.P. Castelli, and M.C. Hjortland High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study Am. J. Med. 62 5 1977 707 714
31. A. Kontush, and M.J. Chapman Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis Pharmacol. Rev. 58 3 2006 342 374
32. N.N. Mehta, R. Li, and P. Krishnamoorthy Abnormal lipoprotein particles and cholesterol efflux capacity in patients with psoriasis Atherosclerosis 224 1 2012 218 221
33. J. Mosiewicz, A. Pietrzak, and G. Chodorowska Rational for statin use in psoriatic patients Arch. Dermatol. Res. 305 6 2013 467 472
34. B. Vanizor Kural, A. Orem, and G. Cimşit Evaluation of the atherogenic tendency of lipids and lipoprotein content and their relationships with oxidant-antioxidant system in patients with psoriasis Clin. Chim. Acta 328 1-2 2003 71 82
35. S. Coimbra, H. Oliveira, and F. Reis Circulating levels of adiponectin, oxidized LDL and C-reactive protein in Portuguese patients with psoriasis vulgaris, according to body mass index, severity and duration of the disease J. Dermatol. Sci. 55 3 2009 202 204